Avenue Therapeutics Inc.

4.29-0.3600-7.74%Vol 49.33K1Y Perf -52.12%
Apr 16th, 2021 09:40 DELAYED
BID4.28 ASK4.37
Open4.65 Previous Close4.65
Pre-Market- After-Market-
 - -%  - -
Target Price
9.00 
Analyst Rating
Strong Buy 1.00
Potential %
93.55 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Market Cap71.85M 
Earnings Rating
Neutral
Price Range Ratio 52W %
15.17 
Earnings Date
10th May 2021

Today's Price Range

4.264.65

52W Range

2.8512.34

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-32.22%
1 Month
-31.72%
3 Months
-25.36%
6 Months
21.09%
1 Year
-52.12%
3 Years
0.00%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ATXI4.29-0.3600-7.74
AAPL133.94-0.5600-0.42
GOOG2 292.53-4.1300-0.18
MSFT258.66-0.8400-0.32
XOM57.220.24000.42
WFC42.730.49001.16
JNJ161.541.15000.72
FB305.56-2.2600-0.73
GE13.54-0.0100-0.07
JPM153.511.34000.88
Earnings HistoryEstimateReportedSurprise %
Q03 2020-0.10-0.0640.00
Q02 2020-0.10-0.11-10.00
Q01 2020-0.17-0.0852.94
Q04 2019--0.32-
Q03 2019-0.32-0.1456.25
Q02 2019-0.57-0.4324.56
Q01 2019-0.44-0.82-86.36
Q04 2018-0.47-0.3819.15
Earnings Per EndEstimateRevision %Trend
12/2020 FY-0.300.00-
3/2021 QR-0.0614.29Positive
6/2021 QR-0.0625.00Positive
12/2021 FY-0.2513.79Positive
Next Report Date10th May 2021
Estimated EPS Next Report-0.06
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume49.33K
Shares Outstanding16.75M
Trades Count403
Dollar Volume193.21K
Avg. Volume282.07K
Avg. Weekly Volume1.15M
Avg. Monthly Volume573.96K
Avg. Quarterly Volume301.79K

Avenue Therapeutics Inc. (NASDAQ: ATXI) stock closed at 4.65 per share at the end of the most recent trading day (a -2.52% change compared to the prior day closing price) with a volume of 315.84K shares and market capitalization of 71.85M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 4 people. Avenue Therapeutics Inc. CEO is Lucy Lu.

The one-year performance of Avenue Therapeutics Inc. stock is -52.12%, while year-to-date (YTD) performance is -21.85%. ATXI stock has a five-year performance of %. Its 52-week range is between 2.85 and 12.34, which gives ATXI stock a 52-week price range ratio of 15.17%

Avenue Therapeutics Inc. currently has a PE ratio of -21.60, a price-to-book (PB) ratio of 47.64, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -79.55%, a ROC of -127.52% and a ROE of -105.53%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Avenue Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.06 for the next earnings report. Avenue Therapeutics Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for Avenue Therapeutics Inc. is Strong Buy (1), with a target price of $9, which is +93.55% compared to the current price. The earnings rating for Avenue Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Avenue Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Avenue Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.52, ATR14 : 0.76, CCI20 : -231.59, Chaikin Money Flow : 0.06, MACD : -0.17, Money Flow Index : 69.48, ROC : -17.84, RSI : 30.39, STOCH (14,3) : 4.62, STOCH RSI : 0.00, UO : 46.62, Williams %R : -95.38), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Avenue Therapeutics Inc. in the last 12-months were: Joseph Vazzano (Sold 3 840 shares of value $46 579 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Avenue Therapeutics Inc.

Avenue Therapeutics Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of an intravenous, or IV, formulation of tramadol HCl, or IV Tramadol, for the management of postoperative pain.

CEO: Lucy Lu

Telephone: +1 781 652-4500

Address: 1140 Avenue of the Americas, New York 10036, NY, US

Number of employees: 4

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

60%40%

Bearish Bullish

50%50%

Bearish Bullish

61%39%

News

Stocktwits